ATLANTA, GA--(MARKET WIRE)--Jul 25, 2008 -- Medspas of America Inc. (Other OTC:MEDP.PK - News), www.medspasofamerica.com, announced today that Dr. Jon Bragi Bjarnason, Chief Executive Officer and Founder of Zymetech Inc., www.zymetech.com, has joined the Company's Advisory Board.

Dr. Bjarnason discovered a highly active marine enzyme off the coast of Iceland that is now known as Penzim. After extensive research on the marine enzyme's wound healing capabilities, Dr. Bjarnason received the worldwide patent for Penzim, the trade name of this enzyme and the main ingredient in Natural Renu's anti-aging product line.

Dr. Bjarnason is a Professor of Biochemistry at the University of Iceland and has served as Chairman, Department of Chemistry, University of Iceland; Chairman, Science Institute, University of Iceland; Visiting Professor, Department of Biochemistry, Colorado State University; Visiting Professor, Department of Microbiology, and is currently a Visiting Professor at the University of Virginia Medical School.

Dr. Bjaranson holds a Bachelor of Science in Chemistry from the University of Iceland and a Ph.D. in Biochemistry from Colorado State University, Fort Collins, Colorado. Dr, Bjarnason has received a fellowship from the Alexander von Humbolt Foundation and a fellowship from NATO.

About Natural Renu

The company has established a new division to penetrate the $5.4 billion cosmeceutical industry under the brand name Natural Renu. The company's new initiative is a line of cosmeceutical products focusing on the anti aging and skin healthcare markets. The company sales efforts are focused primarily through two marketing channels. The first and primary sales channel is Internet Retailing. The second target audience is to exclusive Plastic Surgeons and Dermatology practices, Day spas, Resorts and Medspas around the world.

SAFE HARBOR STATEMENT: Except for historical information contained herein, the statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the operations of a company.

     Investor Contact Information:
      
     Paul Smith
     Investor Relations
     1-866-595-1081
     Email Contact